July 22-25, 2007, Sydney, Australia
HIV and AIDS Articles | |
 Therapy
for Treatment-naive Patients | |
| • | Starting HAART with a Higher CD4 Cell Count Improves Immune Recovery and Reduces the Risk of Disease Progression or Death |
| • | Lowest-Ever CD4 Cell Count Predicts Both AIDS-defining and Non-AIDS-related Illnesses |
| • | Once-daily 1400/100 mg Dose of Fosamprenavir/ritonavir (Lexiva) Is Virologically Effective and Causes Fewer Body Fat Changes than 1400/200 mg Dose |
| • | Tolerability and Antiviral Efficacy of CCR5 Monoclonal Antibody PRO 140 |
| • | Rilpivirine (TMC278) Causes Less Blood Lipid Elevation than Efavirenz (Sustiva) |
| • | 3-year Extended Follow-up of the 2NN Study: Nevirapine (Viramune) versus Efavirenz (Sustiva) |
| • | Lopinavir/ritonavir (Kaletra) Soft Gel Capsules Plus Tenofovir (Viread) as First-line, 2-drug HAART: 48-week Results of the Kalead-1 Study |
| • | Experimental Integrase Inhibitor Elvitegravir Has Additive to Synergistic Interactions with Other Antiretrovirals in vitro and No Relevant PK Drug Interaction with Darunavir/ritonavir or Tipranavir/ritonavir |
| • | Effects of Tipranavir/ritonavir Compared to Lopinavir/ritonavir on Changes in Body Composition and Metabolic Parameters in Treatment-naïve Patients |
| • | Experimental CCR5 Antagonist INCB009471 Shows Sustained Anti-HIV Activity in Early Clinical Trial |
| • | New Maturation Inhibitor May Be More Potent than Bevirimat (PA-457) |
| • | CCR5 Antagonist Maraviroc (Celsentri) Not Quite as Effective as Efavirenz but Better Tolerated in Treatment-naive Patients |
| • | Experimental Integrase Inhibitor Raltegravir Achieves HIV Viral Load Reductions Comparable to Sustiva and Shows a More Favorable Lipid and Tolerability Profile in Treatment-naïve Patients |
| • | Once-daily Ritonavir-boosted Fosamprenavir (Lexiva) or Atazanavir (Reyataz), Both with Tenofovir/emtricitabine in Treatment-naive Patients: 48-week Results of the ALERT Trial |
| • | Effects of Tipranavir/ritonavir Compared to Lopinavir/ritonavir on Changes in Body Composition and Metabolic Parameters in Treatment-naïve Patients |
| • | Impact on Efficacy and Lipid Profiles of Saquinavir/ritonavir (Invirase) vs Lopinavir/ritonavir (Kaletra): The Gemini Study at 24 Weeks |
| • | Lopinavir/ritonavir (Kaletra) Monotherapy Suppresses HIV Viral Load in HIV-1-treatment-naïve Patients: 48-week Results of IMANI-2 |
| • |
|
| • | Nevirapine-based HAART Increases HDL ("Good") Cholesterol in Patients with Sustained HIV Suppression |
| • | Indications of Cross-resistance between Integrase Inhibitors Elvitegravir and Raltegravir |
| • | Risk Factors for Kidney Toxicity in People with HIV |
| • | Ezetimibe Combined with a Statin Is Effective in Lowering LDL Cholesterol and Triglycerides in Patients Treated with Protease Inhibitors |
| • | High Response Rate with Enfuvirtide (Fuzeon) Plus Darunavir (Prezista) Regardless of Existing Protease Inhibitor Resistance |
| • | Efficacy and Safety of Etravirine (TMC125) in Treatment-experienced HIV Patients: 24-week Results from the DUET-1 and DUET-2 Trials |
| • | Switching to Truvada More Effective than Epzicom Due to Abacavir Hypersensitivity |
| • | Safety and Efficacy of Experimental CCR5 Antagonist Vicriviroc in Treatment-experienced HIV Patients: 48 week Results of ACTG 5211 |
| • |
|
| Lipodystrophy
and Metabolic Complications | |
| • | Nutritional Counseling Can Help Prevent Blood Fat Abnormalities in HIV Patients on HAART |
| • | Once-daily 1400/100 mg Dose of Fosamprenavir/ritonavir (Lexiva) Is Virologically Effective and Causes Fewer Body Fat Changes than 1400/200 mg Dose |
| • | Cardiovascular Risk and Associated Metabolic Changes in People with HIV: The CREATE 1 Cohort Study |
| • | Rilpivirine (TMC278) Causes Less Blood Lipid Elevation than Efavirenz (Sustiva) |
| • | Ezetimibe Combined with a Statin Is Effective in Lowering LDL Cholesterol and Triglycerides in Patients Treated with Protease Inhibitors |
| • | "Lipodystrophy" Is Not What It Used to Be: Data from the Swiss HIV Cohort Study |
| • | |
| • | Impact on Efficacy and Lipid Profiles of Saquinavir/ritonavir (Invirase) vs Lopinavir/ritonavir (Kaletra): The Gemini Study at 24 Weeks |
| Adverse
Side Effects | |
| • | Starting HAART at Higher CD4 Cell Counts Reduces Risk of Immediate and Long-term NRTI Side Effects |
| • | Cardiovascular Risk and Associated Metabolic Changes in People with HIV: The CREATE 1 Cohort Study |
| • | Risk Factors for Kidney Toxicity in People with HIV |
| • | Risk of Skin Cancer Elevated in People with HIV |
| • |
|
| Pre-exposure
Prophylaxis (PrEP) | |
| • | PrEP and Timed Intercourse for Conception in Serodiscordant Couples
|
| Drug
Abuse | |
| • | Methamphetamine Use Associated with Lower CD4 Cell Counts in People with HIV |
| • | A Decade of Data Shows Needle Exchange Programs Reduce HIV Risk in Australian Injection Drug Users
|
| HIV
Prevention | |
| • | |
| • |
|
| Children
and Women | |
| • | |
| • | Treating HIV-Infected Infants Early Helps Them Live Longer
|
| |
Hepatitis
B Articles | |
| • | Presence of Mixed Hepatitis B Genotypes Occurs More Frequently in HIV-HBV Coinfected Patients |
| • | Studies Examine Occult HBV Infection in HIV Positive and HIV-HCV Coinfected Patients |
| • | Efficacy and Safety of Boosted Fosamprenavir (Lexiva) versus Lopinavir/ritonavir (Kaletra) in Treatment-naive HIV Patients with Hepatitis B or C Coinfection in the KLEAN Study |
| • | HIV Positive Individuals More Likely to Respond to High-dose HBV Vaccine |
| • | Complete HBV Genome Analysis in HIV Coinfected Individuals Identifies a Novel Core/precore Mutant |
| • | Combination Therapy for Hepatitis B in HIV-HBV Coinfected Patients |
| |
Hepatitis
C Articles | |
| • | CD4 Cell Count Preferred over CD4 Cell Percentage for Monitoring HIV Disease Progression in People with Cirrhosis |
| • | Risk Factors Associated with HIV and HCV Infection among Injection Drug Users in India |
| • | Pharmasset Completes Enrollment for Phase 1 Study of Experimental Nucleoside Polymerase Inhibitor R7128 for Treatment of Chronic Hepatitis C |
| |
Coinfection
Articles | |
| • | Rapid Response to Hepatitis C Treatment Predicts Cure, but Occurs Less Often in HIV-HCV Coinfected Patients |
| • | CD4 Cell Count Preferred over CD4 Cell Percentage for Monitoring HIV Disease Progression in People with Cirrhosis |
| • | Immunological Progression of HIV Disease in HIV-HCV Coinfected Patients on HAART |
| • | Pegylated Interferon plus Ribavirin Slows Liver Cirrhosis Progression in HIV-HCV Coinfected Individuals, Even if Non-responders |
| • | Presence of Mixed Hepatitis B Genotypes Occurs More Frequently in HIV-HBV Coinfected Patients |
| • | Comparison of Non-invasive Methods for Assessing Liver Fibrosis in HIV-HCV Coinfected Individuals |
| • | Studies Examine Occult HBV Infection in HIV Positive and HIV-HCV Coinfected Patients |
| • | Safety of Atazanavir (Reyataz) in HIV-HBV and HIV-HCV Coinfected Patients with Pre-existing Liver Disease |
| • | Risk of Liver Toxicity in HIV Patients Treated with Tipranavir (Aptivus) is Related to Hepatitis C Coinfection and Liver Fibrosis |
| • | Neurological Effects of Active Hepatitis C Virus Infection in HIV-HCV Coinfected Patients on Suppressive HAART |
| • | Efficacy and Safety of Boosted Fosamprenavir (Lexiva) versus Lopinavir/ritonavir (Kaletra) in Treatment-naive HIV Patients with Hepatitis B or C Coinfection in the KLEAN Study |
| • | Risk Factors Associated with HIV and HCV Infection among Injection Drug Users in India |
| Complete HBV Genome Analysis in HIV Coinfected Individuals Identifies a Novel Core/precore Mutant | |
| • | HIV Positive Individuals More Likely to Respond to High-dose HBV Vaccine |
| • | Liver Steatosis Is Common in HIV-HCV Coinfected Patients - Screening Recommended |
| • | Twice-weekly Pegasys Plus Ribavirin Produces Better Response Than Standard Once-weekly Regimen |
| • | HAART Regimens Containing Tenofovir (Viread) or Lamivudine (Epivir) in HIV-HBV Coinfected Patients |
| • | Impact of Antiretroviral Treatment Interruption among HIV-HCV and HIV-HBV Coinfected Patients in the SMART Trial |
| • | Impact of Antiretroviral Treatment Interruption among HIV-HCV and HIV-HBV Coinfected Patients in the SMART Trial |
| • | HCV Sexual Transmission in Men Who Have Sex with Men |
| • | Natural History of Hepatitis C in HIV Positive Individuals in the HAART Era |
| • | Response to Treatment of Acute Hepatitis C in HIV-HCV Coinfected Patients |
| • | Presence of GBV-C Virus Linked to Improved Immune Function in HIV-HCV Coinfected Individuals |
| • | Studies Shed Further Light on Sexual Transmission of Hepatitis C among Men Who Have Sex with Men |
|
